New shot aims to cut bleeding in hemophilia patients

NCT ID NCT07644832

Recruiting now Disease control Sponsor: Shanghai RAAS Blood Products Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental injection called SR604 in 76 adults with hemophilia A, B, or congenital factor VII deficiency. The goal is to see if it is safe and can reduce bleeding episodes. Participants will receive either a single dose or multiple doses, and researchers will monitor side effects and how well it controls bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL FACTOR VII DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital factor VII deficiency factor VII deficiency hemophilia A hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FACTOR VII DEFICIENCY HEMOPHILIA A HEMOPHILIA B

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
COMPLETED

Tianjin, China
Jinan Central Hospital
RECRUITING

Jinan, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine
COMPLETED

Shanghai, China
The First Affiliated Hospital of University of Science and Technology of China
RECRUITING

Hefei, China
The First Hospital of Lanzhou University
RECRUITING

Lanzhou, China
The Second Hospital of Shanxi Medical University
RECRUITING

Taiyuan, China
Xian Central Hospital
RECRUITING

Xi'an, China
Xiangya Hospital of Central South University
RECRUITING

Changsha, China
Zhengzhou People's Hospital
RECRUITING

Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.